Antibiotics

A new study from University of Copenhagen researchers explains how some multidrug-resistant bacteria are able to survive lethal doses of antibiotics through a hibernation-like defense mechanism.

Researchers from the University of Würzburg in Germany discuss the use of marine natural products to fight drug-resistant pathogens.

With an increasing number of Salmonella infections showing resistance to antibiotics, a CDC team set out to determine which strains are most problematic.

Researchers shed light on how oxylipins play a key role in forming the biofilm shield that helps protect disease-causing bacteria against antibiotics.

A new study reveals evidence that a longer course of antibiotics is more effective for treating ear infections in young children.

Following a recent unanimous decision by United Nations General Assembly member states, the intergovernmental organization has announced it will be holding a high-level meeting in 2018 on the fight against tuberculosis (TB), the first-ever meeting of its kind.

An alternative antibiotic treatment regimen for multidrug-resistant tuberculosis (TB) endorsed by WHO shows promising effects in a new study using computer modeling.

In a new study, a team of pediatric hospital researchers found that cutting unnecessary blood cultures in children avoids false positives without resulting in missed sepsis diagnoses.

In a review article, researchers share current understanding of the pathogenesis of type IV T cell-dependent immune-mediated ADRs and review the evidence for diagnostics for T cell-mediated ADRs.

New guidelines released by researchers with the Infectious Diseases Society of America recommend that people with suspected latent tuberculosis infections receive a new generation of diagnostic testing.

Rita Olans, DNP, CPNP-PC, APRN-BC, assistant professor at MGH Institute of Health Professions, discusses how Infectious Disease specialists, pharmacists, and nurses can work together on antimicrobial stewardship.

A recent study examines antibiotic prescribing patterns in children in primary care settings in the United Kingdom, Netherlands, and Italy.

As antibiotic-resistant Pseudomonas aeruginosa infections continue to vex healthcare settings, a new study from University of Georgia researchers offers insight on just how the pathogen works inside the human body.

John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses push and pull incentives that drive antibiotic development.

Microbes found in New York City park soil samples contain an array of microbes capable of producing known pathogen-fighting compounds, along with a large number of recently discovered compounds.

John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses global and national initiatives for the development of new antibiotics.

Researchers from the University of California-San Francisco tested the ability of 2,177 FDA-approved compounds to reduce viral proliferation in Zika-susceptible cells.

John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, explains the economics of antimicrobial development.

Public Health England and the Department for Environment, Food and Rural Affairs researchers in the United Kingdom found drug-resistant E. coli in a large number of chicken samples, while much lower rates of contamination were observed in beef and pork samples.

Lauri A. Hicks, DO, captain, US Public Health Service, director, Office of Antibiotic Stewardship, medical director, Get Smart: Know When Antibiotics Work, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, examines the threat that antibiotic resistance poses to modern medicine.

A recent study lead by researchers from the University of Freiburg analyzed the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals.

John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses the economic opportunities driving the development of new pharmaceuticals.

Researchers in the United Kingdom have found that predatory bacteria can be used to safely treat antibiotic-resistant Shigella infections, which affect more than 1 million people worldwide each year.

Two cases of meningococcal disease strain B have been confirmed at Oregon State University, urging officials to take preventive measures.